Immunome Research
Open Access
ISSN: 1745-7580
+44-77-2385-9429
ISSN: 1745-7580
+44-77-2385-9429
Gavrila B I, Claudia Ciofu, Carina Mihai, Bojinca M, Gabriela Udrea, Stoica V, Ciotaru D, Mihaela Surcel, Adrina Munteanu, Ursaciuc C and Eugenia Panaitescu
Carol Davila University of Medicine and Pharmacy, Romania
Victor Babes National Institute, Romania
Scientific Tracks Abstracts: J Immunome Res
Background: The introduction of biologic therapy has revolutionized the treatment of rheumatoid arthritis (RA). Despite these advances, 20-40% of the patients are declared non-responders to at least one of the therapies. Objectives: Evaluating the predictive role for the response to anti-tumor necrosis factor therapy of rheumatoid factor (RF) isotypes IgM, IgA, anti-cyclic citrullinated peptide (anti-CCP) and the evolution of serum levels of these biomarkers under biologic treatment. We have also assessed the status of this biomarkers and the response to treatment. Methods: Prospective and observational study including 64 patients was followed for 12 months with active RA, uncontrolled by conventional synthetic DMARDs or declared non-responders to one of the biologic DMARDs. Results: Lower baseline titres of RF type IgM (51.36�±95.359 U/ml, p=0.01629), IgA (22.45�±61.256 U/ml, p=0.03336) and anti-CCP (60.82�±26.331 ng/ml, p=0.00011) had predictive value for achieving a good EULAR response at 6 months. Grouping patients in 2 categories (responders/non-responders), we identified significant differences between groups only for anti-CCP and response at 6 months (responders 96.04�±50.355 ng/ml, non-responders 146.16�±41.68 ng/ml, p=0.02834). For the EULAR response at 12 months, lower baseline titres for RF type IgM (92.93�±120.22 U/ml, p=0.01032) and IgA (49.96�±98.08 U/ml, p=0.00247) had predictive value for achieving a good response at 12 months. We didnâ��t obtain other information grouping patients in 2 categories. Monitoring the evolution of serum levels, we noticed reduction in all three biomarkers tested, statistically significant at 6 and/or 12 months from baseline. Regarding the status (positive/negative) pretreatment and the response to anti-TNF agents, we noticed significant differences regarding status for RF IgA isotype and response to treatment at 12 months (p=0.004). Conclusion: It can be concluded that, beside their diagnostic role, these biomarkers can be used for other purposes in RA.
GavrilÃ?Â? B I did his PhD in Internal Medicine, and now he is an Assistant Professor at Dr. I Cantacuzino Clincal Hospital, Department of Internal Medicine and Rheumatology in Bucharest.
Email: bogdang135@yahoo.com